Search results

Icon explanation

close

Abstract

ePoster

Handout

Image

Journal Article

Presentation

Video

Webcast

1. P1874

   In vitro activity of eravacycline and comparators against Gram-positive bacteria collected from European hospitals in 2017

   Ian Morrissey, Monthey, Switzerland

   Ian Morrissey , Nimmi Kothari , Federica Monti , Matteo Bassetti , Sophie Magnet , Stephen Hawser , Melanie Olesky , Corey Fyfe

   15 April 2019

   Session: In vitro activity of newer antibacterial agents

   Relevance:

    

   100%

    

   

   Event: ECCMID 2019
   Amsterdam, The Netherlands
   Abstract publication

   Bacterial Susceptibility & Resistance

2. P1884

   Surveillance of iclaprim activity against Gram-positive cocci, including antibiotic-resistant strains, collected from patients with skin and skin structure infections during 2017 from European and American hospitals

   Ian Morrissey, Monthey, Switzerland

   Ian Morrissey , David Huang , Nadia Tocci , Sophie Magnet , Stephanie Noviello , Stephen Hawser

   15 April 2019

   Session: In vitro activity of newer antibacterial agents

   Relevance:

    

   100%

    

   

   Event: ECCMID 2019
   Amsterdam, The Netherlands
   Abstract publication

   Bacterial Susceptibility & Resistance

3. P2423

   In vitro activities of AAI101, a novel extended-spectrum beta-lactamase inhibitor, and tazobactam, in combination with cefepime, against extended-spectrum beta-lactamase producing Klebsiella pneumoniae clinical isolates

   Ian Morrissey, Monthey, Switzerland

   I. Morrissey, C. de Piano, S. Magnet, S. Hawser, S. Shapiro, P. Knechtle

   24 April 2018

   Session: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

   Relevance:

    

   100%

    

   

   Event: ECCMID 2018
   Madrid, Spain
   Abstract publication

   New Antibacterial Agents & Stewardship

4. P2415

   Activity of the novel extended-spectrum beta-lactamase inhibitor AAI101 in combination with cefepime against Enterobacteriaceae collected from US and European hospitals during 2014/2015

   Ian Morrissey, Monthey, Switzerland

   I. Morrissey, S. Magnet, S. Hawser, S. Shapiro

   24 April 2018

   Session: Beta-lactam/beta-lactamase inhibitor combinations: in vitro and in vivo data

   Relevance:

    

   100%

    

   

   Event: ECCMID 2018
   Madrid, Spain
   Abstract publication

   New Antibacterial Agents & Stewardship

5. P1046

   Global activity of imipenem-relebactam against P. aeruginosa from respiratory tract infections - SMART 2015-2016

   Ian Morrissey, Monthey, Switzerland

   I. Morrissey, S. Lob, K. Kazmierczak, K. Young, M. Motyl, M. Gueny, S. Magnet, A. Soudan, D. Sahm

   22 April 2018

   Session: Carbapenem plus carbapenemase inhibitor combinations: in vitro and in vivo data

   Relevance:

    

   100%

    

   

   Event: ECCMID 2018
   Madrid, Spain
   Abstract publication

   Bacterial Susceptibility & Resistance

6. P1039

   In vitro activity of Nacubactam, a novel dual action diazabicyclooctane, alone and with meropenem, against beta-lactamase-positive Enterobacteriaceae

   Ian Morrissey, Monthey, Switzerland

   I. Morrissey, S. Magnet, S. Hawser, S. Louvel, R. Okujava, C. Zampaloni, K. Bradley

   22 April 2018

   Session: Carbapenem plus carbapenemase inhibitor combinations: in vitro and in vivo data

   Relevance:

    

   100%

    

   

   Event: ECCMID 2018
   Madrid, Spain
   Abstract publication

   New Antibacterial Agents & Stewardship

7. E0006

   Activity of ceftobiprole and comparators against European respiratory-tract isolates of MSSA and MRSA from 2016

   Ian Morrissey, Monthey, Switzerland

   I. Morrissey, S. De Angelis, S. Magnet, S. Hawser, A. Santerre Henriksen

   21 April 2018

   Session: Antibacterial susceptibility and resistance

   Relevance:

    

   100%

    

   

   Event: ECCMID 2018
   Madrid, Spain
   Abstract publication

   Bacterial Susceptibility & Resistance